The company held the second session of the 11th board of directors and the second session of the 10th board of supervisors to examine and approve the annual work report and other relevant proposals.
Release time:
2021-05-06
News from our newspaper # February 24 , Chairman Jiang Xiaomeng of the Group Company presided over the meeting of the 11th Board of Directors of the Company, deliberating and passing 2020 Annual Board of Directors Report, 2020 General Manager Business Report, 2020 Annual Report and other 15 related reports and proposals. The 10th 2 Supervisory Board of the Company was also held on the same day.
Due to the new coronary pneumonia epidemic, the national cement industry was greatly affected in the short term, but the overall operation of the industry was stable throughout the year. 2020 , the company made new progress in the construction of cement projects. The off-site technological transformation project (with waste heat power generation) of the new dry cement production line with a daily output of 4500 tons of clinker in Huangping, Guizhou was completed and put into trial production in 9 . The production license was successfully obtained during the year. All production and operation indexes of the production line basically reached the expected targets. The cement enterprises under the company actively carry out benchmarking management and standardized management, continuously promote the "three reductions and three improvements" activities, steadily implement various technological transformation work, and continuously improve the production efficiency of enterprises while strictly controlling production costs. A total of ,526 tons of cement and clinker were sold throughout the year. Daye Peak has implemented more than 10 technical reforms such as the technical reform of the newly added raw meal online analyzer, the technical reform of the grate cooler, the transformation of the cement mill system, and the transformation of the waste heat power generation DCS . The quality of raw meal has been significantly improved and the standard coal consumption per ton of clinker has decreased. Yunnan Peak has completed the technical renovation of grate cooler, preheater and other equipment, effectively increasing the output of rotary kiln. In addition, the company integrated part of the equity participation in the cement business and sold the equity of Guangxi Huying; participated in the major asset reorganization of Tianshan shares with the equity of Southern Cement held by the company, further optimizing the asset allocation structure.
2020, the reform of the pharmaceutical industry continued to increase, the industry pattern further changed. Jianfeng Pharmaceutical and its subsidiaries further strengthened product research and development and innovation. Paroxetine Hydrochloride Tablets passed the consistency evaluation and obtained the production approval documents of esomeprazole sodium raw materials and injections. Subsidiaries Jianfeng Yien and Zhejiang Erying respectively obtained the clinical approval documents of Class I anti-tumor new drug JFAN-1001 and Class III new drug acetaminophen suppository. Jianfeng Pharmaceutical and its subsidiaries have made progress in a number of technological transformation and engineering construction. The annual output of 20 .6 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical has been included in the key technological transformation project of Jinhua City in 2020 . At present, the civil work of the main project has been basically completed, and equipment installation and debugging, quality system introduction and verification are underway. New North Card and New Peak North Card have fully implemented technical transformation, on the basis of its existing pesticides and pharmaceutical intermediates, it will be upgraded to become a comprehensive R & D and production base for APIs, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of APIs and preparations of Jianfeng Pharmaceutical. Peak Pharmaceutical is also actively exploring new marketing models, further improving the commission-based marketing model and incentive assessment system.
In addition, under continued market regulation, the image of the health care industry and consumer trust have recovered, and under the influence of the new crown epidemic, national health care awareness has been growing and demand for health care products has gradually recovered. Subsidiaries Jianfeng Health, Tianjin Jianfeng Natural Products and Tianjin Flanders have all passed the national high-tech enterprise certification; Jianfeng Health has newly added health food registration approval documents, realizing the customized sales and product development of multiple functional foods; Tianjin Jianfeng Natural Products has updated and optimized the product technology, effectively reducing the production cost; tianjin Flanders has obtained production licenses for special dietary foods (nutritional supplements for pregnant women and lactating mothers) and convenience foods (instant cereals), realizing product transformation. Jianfeng International Trade readjusted the layout of the warehouse base, completed the construction of two new logistics warehouses, further improved the land utilization rate and increased the operation and storage area, and made full use of the storage and transportation advantages of Jinhua South Station to effectively improve the storage and operation capacity. Peak cable through the adjustment of product structure, pay attention to the maintenance and training of large customers, the annual production and sales, profits have increased year-on-year. On the day of
, the company also held the2 meeting of the 10th board of supervisors, deliberating and approving 5 related reports and proposals such as the company's 2020 annual board of supervisors report, 2020 annual financial final accounts report, 2020 annual profit distribution plan, etc. (residual fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31